SIREN : 488068057
FIDASSYL is a French company founded 20 years ago, specialized in the sector Activités des sociétés holding. Based in ABLIS (78660), this company of category PME shows in 2024 a revenue of 900 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 899 710 € | 967 414 € | 1 275 022 € | 959 848 € | 879 858 € | 775 120 € | 895 695 € | 987 639 € |
| Net income | 163 076 € | 296 662 € | 55 637 € | -34 421 € | 24 489 € | -130 404 € | -91 903 € | 50 231 € |
| EBITDA | 92 611 € | 182 924 € | 303 691 € | 203 382 € | 275 701 € | 177 822 € | 207 650 € | 237 331 € |
| Net margin | 18.1% | 30.7% | 4.4% | -3.6% | 2.8% | -16.8% | -10.3% | 5.1% |
In 2024, FIDASSYL achieves revenue of 900 k€. Activity remains stable over the period (CAGR: -1.3%). Slight decline of -7% vs 2023. After deducting consumption (0 €), gross margin stands at 900 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 93 k€, representing 10.3% of revenue. Warning negative scissor effect: despite revenue change (-7%), EBITDA varies by -49%, reducing margin by 8.6 pts. This reflects costs rising faster than revenue. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 163 k€, i.e. 18.1% of revenue. This profit can be retained or distributed to shareholders.
899 710 €
899 710 €
92 611 €
-4 725 €
163 076 €
10.3%
The debt ratio (= Financial debt / Equity x 100) stands at 43%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 68%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 4.8 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 28.1% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
42.666%
67.647%
28.097%
4.775
6.3%
In 2024, the debt ratio of FIDASSYL (42.67) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of FIDASSYL (67.7%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of FIDASSYL (4.78) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 117.06. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 42.0x. Operating income very largely covers interest expenses: high safety margin.
117.059
41.95
In 2024, the liquidity ratio of FIDASSYL (117.06) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of FIDASSYL (42.0x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 40 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 41 days. Favorable situation: supplier credit is longer than customer credit by 1 days. Overall, WCR represents 12 days of revenue, i.e. 31 k€ to permanently finance. Notable WCR improvement over the period (-82%), freeing up cash.
30 770 €
40 j
41 j
0 j
12 j
Based on 54 transactions of similar company sales
in 2024,
the value of FIDASSYL is estimated at
430 460 €
(range 167 141€ - 818 398€).
With an EBITDA of 92 611€, the sector multiple of 4.8x is applied.
The price/revenue ratio is 0.59x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare FIDASSYL with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of FIDASSYL in 2024 is 900 k€.
Yes, FIDASSYL generated a net profit of 163 k€ in 2024.
The headquarters of FIDASSYL is located in ABLIS (78660), in the department Yvelines.
The tax return of FIDASSYL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
FIDASSYL operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.